-       Report 
   - June 2024
    -  140 Pages 
    Africa, Middle East
   
   From       €3478EUR$3,869USD£3,050GBP 
                -       Report 
   - April 2023
    -  160 Pages 
    Global
   
   From       €4448EUR$4,949USD£3,901GBP 
                -       Report 
   - April 2023
    -  147 Pages 
    Global
   
   From       €4448EUR$4,949USD£3,901GBP 
                -       Report 
   - March 2023
    -  147 Pages 
    Global
   
   From       €4448EUR$4,949USD£3,901GBP 
                -       Report 
   - September 2024
    -  128 Pages 
    Global
   
   From       €13478EUR$14,995USD£11,820GBP 
                 -       Drug Pipelines 
   - July 2022
    -  71 Pages 
    Global
   
   From       €8984EUR$9,995USD£7,879GBP 
                -       Report 
   - August 2022
    -  112 Pages 
    Global
   
   From       €1798EUR$2,000USD£1,577GBP 
                -       Report 
   - November 2024
    -  75 Pages 
    Global
   
   From       €3500EUR$4,171USD£3,177GBP 
                -       Report 
   - May 2023
    -  79 Pages 
    Global
   
   From       €3500EUR$4,171USD£3,177GBP 
                -       Report 
   - May 2023
    -  109 Pages 
    Global
   
   From       €3500EUR$4,171USD£3,177GBP 
                -       Report 
   - November 2023
    -  122 Pages 
    Global
   
   From       €3500EUR$4,171USD£3,177GBP 
                -       Report 
   - January 2025
    -  132 Pages 
    Global
   
   From       €854EUR$950USD£749GBP 
               
         The Bronchodilator market is composed of inhalers and nebulisers, both of which are used to treat respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Inhalers are handheld devices that deliver medication directly to the lungs in the form of a mist or spray. Nebulisers are larger machines that convert liquid medication into a fine mist that can be inhaled. Both inhalers and nebulisers are used to deliver bronchodilators, which are medications that relax the muscles    in the airways and make it easier to breathe.
Inhalers are the most commonly used form of bronchodilator delivery, as they are more convenient and cost-effective than nebulisers. Inhalers come in a variety of forms, including metered dose inhalers (MDIs), dry powder inhalers (DPIs), and soft mist inhalers (SMIs). Nebulisers are typically used for more severe cases of respiratory conditions, as they can deliver a higher dose of medication than inhalers.
Some of the companies in the Bronchodilator market include GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, and Merck. Show Less   Read more